

**JAK2 Exon 12 and Other Non-V617F Mutation
Detection, Bone Marrow**

Patient ID SA00100556	Patient Name TESTINGRNV, REPORT	Birth Date 1999-11-11	Gender M	Age 17
Order Number SA00100556	Client Order Number SA00100556	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 08 Nov 2017 06:00		

JAK2 Exon 12 Mutation Detection, BM

JAK2 Sequencing Result

MCR

see interpretation

Final Diagnosis:

1 MCR
Bone marrow, JAK2 exons 12–15 genetic alteration analysis:

Negative. No genetic alterations were detected in JAK2 , exons 12–15.

A negative test result does not exclude the possibility of a myeloproliferative neoplasm (MPN). The sensitivity of this assay is approximately 20%, such that samples containing lower percentages of mutated nucleic acid may not be identified. If clinical suspicion is high for polycythemia vera, the test JAK2 V617F Mutation Detection (Test ID: JAK2B, JAK2M, or JAK2V) should be considered to obtain a sensitive screen for the JAK2 V617F alteration. If clinical suspicion is high for primary myelofibrosis (PMF) or essential thrombocythemia (ET), consider

additional testing using the Myeloproliferative Neoplasm, JAK2 V617F with Reflex to CALR and MPL test (Test ID: MPNR), which reflexively tests for the presence of a JAK2 V617F, CALR, or MPL alteration. Clinicopathologic correlation is recommended for a definitive diagnosis.

Signing Pathologist: Melissa Tricker-Klar

ADDITIONAL INFORMATION

Method summary - JAK2 exons 12–15 mutation analysis: Total RNA was extracted and converted to cDNA, followed by Sanger sequencing of JAK2, exons 12–15 (see Mayo Clinic Laboratories Interpretive Handbook for method details). The sensitivity of this assay is approximately 20%, such that samples containing lower percentages of mutated nucleic acid will appear negative. The reference gene transcript used for variant annotation is: GRCh37(hg19)NM_004972.3.

Received: 08 Nov 2017 16:14

Reported: 08 Nov 2017 17:18

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292